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Introduction
Colorectal cancer is the second most common cause of
cancer death in EU countries [1]. Molecular biology
creates hopes for the recognition of all the mechanisms
responsible for colorectal carcinogenesis and further
progression of the disease. However, many interactions
between molecular alterations and pathological and
clinical features still remain unknown [2, 3]. Oncogenic
proteins may accompany particular genetic alterations
[2, 4-6]. The correlation between the expression of
selected oncoproteins and the pathological and clinical
features observed in neoplasmatic diseases have been the
subject of many studies [2, 6, 7]. Observations of selected
oncoproteins in different malignancies can be helpful
for predicting more aggressive tumor potential or for
determining its response to therapy. Blocking the receptor
c-erbB2 protein of the c-erbB2 gene (also known as 
Her-2/neu) on the surface of cancer cells with trastuzumab
has become part of the standard management of breast
cancer patients [8-10]. Interfering EGFR signaling with
Cetuximab decreases drug resistance in the treatment of
colorectal cancer, whereas blocking VEGF with
bevacizumab inhibits neoangiogenesis in primary tumors
and metastases of colorectal cancer [8, 11]. The presence
of selected antigenic components of the members of
epithelial growth factor receptor family on the cell surface
of the primary and secondary tumors of the breast, colon
and pancreas promotes studies on the immunotherapy
of these neoplasms [6, 12-15]. Four different receptors
with tyrosine kinase activity are included into the
epidermal growth factor receptor family: c-erbB1
(EGFR), c-erbB2, c-erbB3 and c-erbB4, while c-erbB1
and c-erbB2 show significant structural similarity [13, 16].
c-erbB2 is a 185-kDA cell membrane glycoprotein. It
plays a part of a regulatory switch between cell diffe-
rentiation and proliferation of epithelial cells [13, 17]. 
c-erbB2 activity favors cells proliferation, prolongation
of their survival time, and promotes neoangiogenesis and
tumor dissemination [7, 9, 16]
c-erbB2 gene is located on chromosome 17, together
with the p53 suppressor gene, which is of great im-
portance in oncogenesis. The expression of mutated p53
protein in primary colorectal cancer may be an indicator
of poorer prognosis, although the prognostic value of p53
has not been clearly determined [20-22]. p53 gene
alterations can affect the chemo- and radiosensitivity of
many neoplasms, including colorectal tumors [18, 23, 24].
Correlations between p53 and c-erbB2 expression and
prognosis were observed in patients with breast cancer,
and also in gastric cancer patients [25, 26]. It was found
that p53 gene mutation in breast cancer patients free of
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lymph node metastases has an independent negative
prognostic value only in the presence of c-erbB2
amplification [27].
About 1/3 of Dukes B colorectal cancer patients will
experience disease recurrence [28]. In almost a half of
the radically treated colorectal cancer patients distant
metastases will occur in the follow up period [29]. c-erbB2
and mutated p53 proteins take part in colorectal
oncogenesis and tumor progression [2, 30, 31].
The aim of this study was to estimate the prognostic
value of simultaneously evaluated c-erbB2 and p53
proteins in surgically treated colorectal cancer.
Material and method
Pa t i e n t s
107 consecutive patients (45 women (42.1%) and 62 men
(57.9%)) with T2–T4 resectable adenocarcinoma of the colon
were enrolled in the study. The patients were operated in the
Department of Surgical Oncology of the Medical University in
Gdaƒsk between October 1997 and December 2000. Age range
was 31-85 years, mean 64.8 yrs. median 67 yrs. The primary
tumor was located in the colon in 53 cases, and in the rectum in
54 cases. The follow up period was completed by the end of
November 2004. Eighty eight patients were treated by radical
resection (38 with colon and 50 with rectal tumors). In this
group we had performed 16 right and 5 left hemicolectomies, 17
sigmoidectomies, 34 anterior resections, 11 Miles’ operations,
and 5 Hartmann’s procedures In 3/88 patients with solitary liver
metastases radical metastasectomy was performed. Nineteen
patients underwent palliative tumor resection: 12 presented with
disseminated disease, and non-radical R1 resection was
performed in 7 cases. Patients receiving neoadjuvant treatment
were not enrolled into the study. Standard adjuvant therapy was
administered depending upon the stage of the disease [32].
Median follow up was 48 months. Median survival time was 59
months. Of the 107 patients, 56 (52%) died (50 from colorectal
cancer recurrence, 1 from dissemination of lung cancer as
a second neoplasm, in 5 patients the cause of death remained
unknown). The histological type of the tumor was evaluated
according to the WHO classification [33]. Tubular adeno-
carcinoma was found in 91 cases (85%) and mucinous adeno-
carcinoma in 16 cases (15%). Histological differentiation was
classified as G1 in 13 cases (12.1%), G2 in 64 cases (59.8%)
and G3 in 30 cases (28.8%). All mucinous carcinomas were
scored as grade G3 [34]. Staging was assessed according to
pTNM classification [35]. There were 23 T2 tumors (21.5%),
77 T3 (72%), and 7 T4 tumors (6.5%). In 50 cases (46.7%)
metastatic regional lymph nodes were observed (N1 – 31 (29%),
N2 – 19 (17.7%)). Stage I disease was diagnosed in 17 patients
(15.9%), stage II in 38 (35.5%), stage III in 37 (34.6%) and
stage IV in 15 cases (14%).
I m m u n o h i s t o c h e m i c a l  a n a l y s i s
Sections from formalin-fixed, paraffin-embedded material
retrieved from the archives of the Department of Pathology of
the Medical University in Gdaƒsk were evaluated for c-erbB2
and p53 proteins expression. Specimens without necrosis were
chosen for imunohistochemistry. Staining was evaluated at the
tumor base, at the point of the deepest tumor infiltration. For
immunohistochemical staining of c-erbB2 we used the rabbit
polyclonal antibody A 0486 (DAKO) diluted 1:40. Immuno-
histochemical staining for p53 was carried out with mouse
monoclonal antibody M 7001 (clone DO-7) diluted 1:50. All
the immunohistochemical procedures were performed according
to the instructions recommended by the manufacturers. The
presence of the antigen-antibody complexes was revealed by
adding biotinylated secondary antibodies and the streptavidin-
peroxidase complex (LSAB system, DAKO K0675). Diamino-
benzidine (DAB) was used as chromogen. Additionally, the
sections were counterstained with Meyer hematoxilin. According
to the common technique the membranous staining was
semiquantitavely scored estimating the c-erbB2 protein
expression in tumor cells as 0, no staining or membrane staining
in less than 10% of cells; 1+, incomplete membrane staining is
observed in more than 10% of cells; 2+, a weak to moderate
complete membranous staining detected in more than 10% of
cells; 3+, a strong complete membranous staining detected in
more than 10% of cells (14.36). Scores 2+ and 3+ were
considered as protein overexpression. p53 expression was
interpreted positive when nuclear staining of over 30 % cells
was detected [37]. Figures 1 and 2 present consecutive cases
with c-erbB2 and p53 overexpression.
S t a t i s t i c a l  a n a l y s i s
Data analysis was performed with the use of Statistica 7.0
(StatSoft Inc. Tulsa, OK, USA). The correlations between
the investigated parameters (n=107) were tested by Pearson
chi2 statistics with the Yates exact test correction (p<0.01 for
statistically significant differences). Survival analysis (n=88)
was performed with the Kaplan-Meier method and compared
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Figure 1. c-erbB2 membranous protein overexpression (3+) 
in cancer cells (x400)
Figure 2. p53 protein expression in cancer cells (x200)
using the log-rank test (p<0.05 for statistically significant
differences).
Results
We observed no membranous c-erbB2 protein expression
(grade 0) in 49 cases (45.8%), grade 1+ in 32 cases
(29.9%), grade 2+ in 20 cases (18.7%), and grade 3+ in 6
cases (5.6%). Overexpression (grade 2+ and 3+) was
present in 26 primary tumors (24.3%). p53 protein was
expressed in 62 specimens (57.9%). Both proteins: c-
erbB2 overexpression and p53 positivity were observed in
16 cases (15%). There were no statistically significant
correlations between c-erbB2 and/or p53 expression,
neither in relation to each other nor to the commonly
estimated pathoclinical features of the disease, such as
tumor location, WHO tumor type, depth of bowel wall
infiltration, regional lymph node involvement, distant
metastases, tumor differentiation and patient age and
gender (n=107). We observed some slight tendencies
between more frequent mutual c-erbB2 overexpression
and p53 among younger patients (p=0.07), in case of
mucinous adenocarcinoma (p=0.08), and in those cases
when the tumor was located in the rectum (p=0.06)
(Table I). The univariate analysis performed in the group
of radically treated patients (n=88) did not show any
correlation between the tested protein expression and
survival time, also in the cases of mutual expression of p53
and c-erbB2 (Table II). This observation rendered the
multivariate analysis using Cox’s multiple regression
model useless in the course of our study.
Discussion
The routine prognostic factors derived from TNM
classification do not allow for the precise prediction of the
course of disease nor for the estimation of tumor cell
sensitivity to adjuvant therapy in radically treated
colorectal cancer patients [29]. It is likely, that the variety
of alternative pathways in colorectal carcinogenesis and
intratumor genetic heterogeneity are responsible for the
different course of the disease in patients with
pathoclinically similar colorectal tumors [3, 38]. The
recognition of additional factors responsible for primary
tumor development and disease dissemination can be
helpful in planning proper treatment and follow up of
colorectal cancer patients. The determination of the role
of membranous c-erbB2 overexpression in ductal breast
cancer as an indicator of more aggressive cancer behavior
and of the sensitivity to trastuzumab and other drugs has
become a great diagnostic and therapeutic success [8-10].
The wide spread of unified methods for the evaluation of
c-erbB2 protein expression, such as the HercepTest® has
rendered research easier [14, 36, 39]. Clinical trials with
trastuzumab have also been undertaken in colorectal
cancer patients with c-erbB2 overexpression, and some
clinical benefits have been observed [32].
The use of polyclonal antibodies A 0485 by DAKO
provides similar results of membranous c-erbB2
evaluation as those observed after processing antibodies
from the original HercepTest®, and the procedure is less
expensive [40]. We applied the A 0485 DAKO antibodies
in our study.
Due to the fact that membranous c-erbB2 over-
expression in breast cancer cells is the result of c-erbB2
gene amplification, FISH (fluorescence in situ hybridi-
zation) is commonly used to reveal the number of c-erbB2
gene copies, and to confirm protein overexpression
diagnosed immunohistochemically. Both FISH and
immunohistochemistry are equivalent in case of 3+ 
c-erbB2 overexpression in breast cancer [39]. In 2+ cases
there exists significant discrepancy of the results obtained
with the use of the two methods, and complementary
estimation by FISH to immunohistochemical evaluation
of protein expression is recommended. However, this
significantly increases the costs of diagnosis [39, 41]. Gene
amplification may be also confirmed by PCR (polymerase
chain reaction) [41]. Distinctly from breast cancer cells
in the case of colorectal cancer cells with membranous
overexpression of c-erbB2 the c-erbB2 gene amplification
is rarely observed, or not observed at all. If gene
amplification is observed in colorectal cancer cells, it does
not necessarily correlate with c-erbB2 membranous
protein overexpression [41-43]. Thereby the expensive
FISH procedure appears not to be as valuable in case of
this malignancy, as it is in breast cancer, and we have not
performed it in the course of our evaluation. The
mechanisms leading to c-erbB2 protein accumulation in
breast and colorectal cancers differ, with suggestions
of presence of alterations at the transcription level in
case of the breast, and at the level of translation and
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Table II. Univariate analysis of investigated features (n=88)
Variable p value
c-erbB2 0/1+ vs. c-erbB2 2+/3+ 0.75
p53 (-) vs. p53 (+) 0.26
p53 (+) and c-erbB2 2+/3+ vs other combinations 0.78
Table I. Selected pathoclinical features 
in relation to the mode of c-erbB2 and p53
expression (n=107)
0 1 2 p value
age ≤ 67 years 17 25 9
age >67 years 18 31 7 p=0.07
colon 23 24 6
rectum 12 32 10 p=0.06
adenocarcinomas 29 51 11
adenocarcinoma mucinosum 6 5 5 p=0.08
0 – c-erB2 0/1+ and p53 negative
1 – c-erbB2 2+/3+ and/or p53 positive
2 – c-erbB2 2+/3+ and p53 positive
posttranslational events in the case of the colorectum
[43]. However, there are also well documented reports
stating that gene amplification precedes membranous c-
erbB2 overexpression in colorectal cancer cells [41, 44,
45]. The authors of these reports have estimated protein
overexpression at a level not exceeding 3% to 5% of
cases.
According to many studies, membranous c-erbB2
overexpression in colorectal cancer cells is more rare than
in breast cancer cells [14, 41-43]. Usually the authors
determine between a few percent and anything between
10-20% of cases with membranous c-erbB2 over-
expression [14, 32, 41, 42, 44-47]. However, there are also
reports, where membranous c-erbB2 overexpression is
determined in more than 40-60% of cases [6, 48]. These
discrepancies may be, to some extent, explained by the
diversity of antibodies and examination methods which
are applied. The rarity of protein overexpression limits
clinical trials on the efficacy of trastuzumab in colorectal
cancer patients [32].
We have observed c-erbB2 overexpression in 24.3%
of our patients, and only 5.6% of the examined tumors
presented with level 3+. This observation does not differ
considerably from other reports. Also, we did not observe
any statistically significant correlation between protein
overexpression and survival time or any other patho-
clinical features of the neoplasmatic disease as is the case
with other literature reports [30, 47-49]. Some authors
indicate worse prognosis in cases with membranous c-
erbB2 overexpression in colorectal tumors [6]. They
support the hypothesis that c-erbB2 up-regulation is
associated with tumor progression and its metastatic
phenotype, as they usually also observe chromosomal
gains at the c-erbB2 locus 17q in primary and secondary
tumors. A tendency towards better survival has been
observed in case of protein overexpression by a group of
authors who had analyzed 156 colorectal cancer patients
[49]. There also exist literature reports indicating worse
prognosis in case of c-erbB2 protein overexpression [6].
Some authors report a positive correlation between
c-erbB2 and better tumor differentiation despite
differences in methodology, nevertheless without any
correlation to survival time or other pathoclinical features
[30, 44]. In their opinion c-erbB2 may contribute to tumor
morphogenesis and tubular structures.
Many studies support the theory of colorectal cancer
following an adenoma – carcinoma sequence [2, 31].
Alterations in the p53 gene, the so called “guardian of
the genome” play a very important part in this process
[2, 18, 19, 31]. They usually result in mutated p53 protein
production and accumulation [5, 31]. Although there is no
agreement as to the prognostic role of p53 in colorectal
cancer, a majority of reports indicate its negative
association with prognosis [20, 22, 31]. The combination
of data on p53 expression combined with data concerning
other potentially prognostic factors may enhance the
probability of correct prognosis [21]. The simultaneous
existence of the p53 mutation and the c-erbB2 amplifi-
cation possesses independent negative prognostic value in
breast cancer patients without metastases to regional
lymph nodes [27]. A statistically significant correlation
has been observed between p53 and c-erbB2 expression in
gastric cancer [25]. The coexistence of both these
alterations is associated with more aggressive tumor
behavior, although the authors of this particular paper
have failed to provide some kind of explanation of this
phenomenon. Other authors have performed evaluations
of the immunohistochemical expression of five different
proteins in resectable colorectal cancer: nm23, p53, 
c-erbB2, u-PA and VEGF [7]. p53 tended to correlate
with liver metastases, and c-erbB2 did not show any inter-
dependences. No correlations between p53 and c-erbB2
proteins were observed in the course of a study of 156
radically treated colorectal tumors, and p53 tended to
correlate with worse prognosis [49]. We found p53
positive expression in 57.9% of tumors. We did not find
any statistically significant correlations, neither between
the mutual expression of the two investigated proteins
nor between their expression and patient survival or in
relation to other patho-clinical data, such as tumor
location, WHO tumor type, depth of bowel wall
infiltration, regional lymph node involvement, distant
metastases, tumor differentiation and patient age and
gender. We observed minor tendencies towards more
frequent mutual c-erbB2 overexpression and p53 in
younger patients (p=0.07), in case of mucinous adeno-
carcinoma (p=0.08), and in cases of rectal localisation
of the tumor (p=0.06) (Table I). We assume that the lack
of any correlations in our study may be associated with
a rather small number of tumors exhibiting c-erbB2
overexpression in our patient material.
Contrary to breast cancer cells, in the case of
colorectal cancer cells cytoplasmic c-erbB2 is, pre-
dominantly, present [42-44, 48]. It appears in as many as
68.5% to 87% of colorectal tumors. The estimated
prognostic value of cytoplasmic c-erbB2 in colorectal
cancer patients varies distinctly from the negative to the
positive [42, 48].
The different mechanisms leading to c-erbB2
accumulation in colorectal and breast cancers, and the
diversity of cellular protein distribution suggest the
different role of this protein in the biology of these two
malignancies. It is necessary to unify the methodology of
c-erbB2 protein expression in colorectal cancer cells,
which could help to enroll larger patient groups with the
overexpression of this particular protein and, thus, allow
to perform reliable statistics on its prognostic role. We did
not reveal any prognostic value of membranous c-erbB2
overexpression. The evaluation of p53 expression did not
contribute to a more adequate estimation of prognosis
in the investigated group of patients.
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